//Your Connection to the Life Sciences Industry
Connect to IBC:LinkedIn iconTwitter iconFacebook iconBlog iconRSS icon
EmailPrint

Registration

Online Registration is Open!
Register by Friday, February 27 to Save Up to $500 & Attend the Tuesday night evening networking reception for Free! (a $125 value)!

Download Brochure

Add to Outlook Calendar

Find Another IBC Event

Cell Line Development & Engineering

CSS

Improve Aspects of Bioproduct Development by Leveraging Cutting-Edge Technical and Process Innovation

May 18-20, 2015 | Parc 55 Hilton | San Francisco, CA

Alt Language

Alternative Language Options:

  • Japanese
  • Korean
  • Taiwanese
  • Chinese

SurveyMonkey

We Want Your Opinion! Help us better understand where the biggest opportunities are to advance cancer therapeutics. » Please share your insights

Agenda

Agenda

  Download the Agenda-at-a-Glance PDF, featuring all 3 co-located events

Monday, May 18, 2015

7:00
Registration and Coffee

8:00
Chairperson's Remarks
Thomas Kelly, Associate Scientist II, J&J Biotechnology Center of Excellence

High-Throughput Platforms for Cell Line Development

Featured Presentation

8:15
CRISPR Design and Specificity for Cell Line Development
Ben Haley, Ph.D., Scientist, Genentech

8:45
Rapid Production of Recombinant Proteins in CHO Using Large-Scale Transfection or Stable Pools
Yves Durocher, Ph.D., Team Leader, Recombinant Protein Production - NRC Human Health Therapeutics Portfolio, National Research Council Canada

9:15
Validating the ClonePix as a Method to Assure Clonality
Thomas Kelly, Associate Scientist II, J&J Biotechnology Center of Excellence

9:45
Networking Refreshment Break in Poster and Exhibit Hall

10:10
Chairperson's Remarks
Thomas Kelly, Associate Scientist II, J&J Biotechnology Center of Excellence

High-Throughput Platforms for Cell Line Development (continued)

10:15
An Integrated Cell Line Development Platform for Generation of High Yielding CHO and 293 Stable Cell Lines Expressing Monoclonal Antibodies and Recombinant Viral Glycoproteins
Althaf I. Hussain, Ph.D., Director, Cell Line and Preclinical Development [C], Vaccine Production Program Laboratory,Vaccine Research Center, NIAID/NIH

10:45
A High-Throughput Multi-Parametric Clone Screening Approach for the Generation of Production Cell Lines
Kim Le, Senior Associate Scientist, Cell Line Development, Amgen Inc.

11:15
Genome-Wide RNAi Screen Led to Discovery of Important Genes for Recombinant Protein Production
Su Xiao, Pre-doctoral IRTA Fellow, Biotechnology Core Laboratory, National Institute of Diabetes and Digestive and Kidney Diseases, NIH

11:45
Technology Workshop Presentations

12:15
Networking Luncheon in Poster and Exhibit Hall

1:25
Chairperson's Remarks
Kevin J. Kayser, Ph.D., Director, Cell Culture Development, SAFC

High-Throughput Platforms for Cell Line Development (continued)

1:30
Rapid Production of Recombinant Proteins and Stable Cell Lines
Success means getting to market fast. Therefore, fast and efficient protein production for drug candidate development, characterization, and selection is critical. Creating a stable cell line for clinic trial takes months to more than a year for complicated proteins. High efficiency, scalable electroporation can reduce stable cell line development timelines by up to 50%, even in difficult-to-transfect cell lines. In this presentation, data will show the rapid production of proteins and cell lines at different scales.
Weili Wang, Ph.D., Principal Scientist, Protein Production, MaxCyte

Progress in Host Cell Engineering

2:00
Late-Breaking Presentation

2:30
Metabolic Flux Analysis
Neil Templeton, Ph.D., Senior Scientist, Bioprocess Development, Merck Research Laboratories

3:00
Networking Refreshment Break in Poster & Exhibit Hall

Progress in Host Cell Engineering (continued)

3:30
Adventitious Agent Contamination Risk Mitigation: Engineering MMV Virus Resistance into CHO Cells
Kevin J. Kayser, Ph.D., Director, Cell Culture Development, SAFC

4:00
MicroRNAs and Apoptosis in CHO Cell Culture- Application for Enhanced Biological Production
Joseph Shiloach, Ph.D., Head, Biotechnology Core Laboratory NIDDK, NIH

Panel Discussion:

4:30
Strategies for Optimal Host Cell Engineering
Moderator: Kevin J. Kayser, Ph.D., Director, Cell Culture Development, SAFC

5:00
Networking Cocktail Reception in Poster and Exhibit Hall

6:00
Dinner Discussions
(Additional registration fee required - see registration page for details)
Please join us for this highly interactive 3 hour evening exchange in a roundtable format, which encourages participants to share their experiences and concerns amongst several discussion topics that include:
  • GPCRs, Ion Channels and Other Membrane Targets - The Next Hot Targets! Why? What are the Challenges?
    Moderator: Catherine Hutchings, Ph.D., Antibody Alliance Management & Strategic Partnering, Heptares Therapeutics Ltd., United Kingdom
  • Delivery Approaches for Intracellular Biologics
    Moderator: Paul Watt, Ph.D., Chief Scientific Officer, Phylogica Ltd., Australia
  • Strategies for Plasma Half-Life Extension of Biopharmaceuticals
    Moderator: Arne Skerra, Ph.D., Professor, Chief Scientific Officer, XL-protein GmbH, Germany
  • Non-Antibody Targeting Moieties
    Moderator: Robert Lutz, Ph.D., Vice President, Translational Research and Development, ImmunoGen, Inc.
  • Clinical Translatability of Current ADC Programs: Does Patient Selection/Tailoring Improve Success
    Moderator: Alan C. Rigby, Ph.D., Vice President, ADC Biology, Eli Lilly and Company
  • Site-Specific Conjugation and its Progress Towards Clinical Development
    Moderator: Jagath Reddy Junutula, Ph.D., Vice President, Antibody Discovery & Development, Cellerant Therapeutics, Inc.
  • CRISPR's Influence on Therapeutic Development
    Moderator: Ben Haley, Ph.D., Scientist, Genentech
  • What Technological Breakthroughs will Make a Difference to Cell line Development: Enthusiasm Tempered by Realism
    Moderator: Alan Dickson, Ph.D., Professor of Biotechnology, Director, Centre of Excellence in Biopharmaceuticals, Co-Director, BioProNET, The University of Manchester, United Kingdom
  • Cell Line Authentication
    Moderator: Leonard P. Freedman, Ph.D., President, Global Biological Standards Institute

Tuesday, May 19, 2015

7:30
Coffee

8:00
Chairperson's Remarks
Susan Sharfstein, Ph.D., Associate Professor of Nanobioscience, Colleges of Nanoscale Sciences and Engineering, SUNY Polytechnic Institute

Utilizing Systems Biology for CHO Cell Engineering

8:15
Chinese Hamster Ovary Cell -omics 2.0
Colin Clarke, Ph.D., NIBRT Investigator, National Institute for Bioprocessing Research and Training, Ireland

8:45
Production of a Bioengineered Heparin, Cell Engineering and Bioprocess Considerations
Susan Sharfstein, Ph.D., Associate Professor of Nanobioscience, Colleges of Nanoscale Sciences and Engineering, SUNY Polytechnic Institute

Featured Presentation

9:15
Stable Glycoengineering of CHO Cells
Claus Kristensen, Ph.D., Professor, University of Copenhagen

9:45
Networking Refreshment Break in Poster and Exhibit Hall

10:25
Chairperson's Remarks
Susan Sharfstein, Ph.D., Associate Professor of Nanobioscience, Colleges of Nanoscale Sciences and Engineering, SUNY Polytechnic Institute

Utilizing Systems Biology for CHO Cell Engineering (continued)

10:30
Consequences of Recombinant Protein Load on CHO Cells
Alan Dickson, Ph.D., Professor of Biotechnology, Director, Centre of Excellence in Biopharmaceuticals, Co-Director, BioProNET, The University of Manchester, United Kingdom

11:00
Understanding Genomic Stability of CHO Cells from Cytogenetics to Sequence Variation
Vaibhav Jadhav, Ph.D., Scientist, Austrian Centre of Industrial Biotechnology GmbH, Austria

11:30
Technology Workshop Presentations

12:00
Networking Luncheon in Poster and Exhibit Hall

1:25
Chairperson's Remarks
Richard Neve, Ph.D., Scientist, Discovery Oncology, Genentech

Cell Line Authenticity

Featured Presentation

1:30
Leonard P. Freedman, Ph.D. Irreproducibility: Changing the Policies and Culture of Cell Authentication
Leonard P. Freedman, Ph.D., President, Global Biological Standards Institute

2:00
Improving the Culture of Cell Culture: Addressing the Need for Cell Line Authentication, Quality Control and Annotation
Richard Neve, Ph.D., Scientist, Discovery Oncology, Genentech

2:30
Assessment of Clonality for Production Cell Lines via High-Resolution Imaging
Melisa Carpio, Senior Research Associate II, Cell Engineering, Takeda California

3:00
Networking Refreshment Break and Last Chance for Poster and Exhibit Viewing

Improving Product Quality, Biosimilarity, and Assuring Clonality and Stability

3:45
Three Steps to Start You on the Path to Obtaining the "Best' Recombinant CHO Cell Line: Host Cell Line, Vector and Cell Line Development Process
Alison Porter, Head of Mammalian Cell Culture R&D, Fujifilm Diosynth Biotechnologies

4:15
Improving Efficiency, Productivity and Timelines in Cell Line Development through Site-Specific Integration Technology
Mara Inniss, Post-Doctoral Fellow, Pfizer

4:45
Close of Tuesday Sessions

5:00
Join Us... Happy Hour @ Pier 39 Overlooking San Francisco Bay
This networking reception is at Players Sports Grill & Arcade, which has sweeping views of San Francisco Bay. Enjoy buffet finger food and drinks (beer, wine, soft drinks) plus arcade games and pool tables. Transportation will be provided. Limited tickets for this event remain for an additional $125 fee. If you want to register for this reception, please stop by the registration desk to reserve your spot.

Wednesday, May 20, 2015

7:30
Coffee

8:00
Chairperson's Remarks and Announcement of Poster Awards
Kevin J. Kayser, Ph.D., Director, Cell Culture Development, SAFC

Innovation with Alternative Expression Systems and Novel Host Cell Lines

8:15
Use of the Site-Specific Retargeting Jump-In Platform Cell Line to Support Biologic Drug Discovery
Robin Butler, BSc, Senior Manager, R&D, MedImmune

8:45
Development of a Human Host Cell Line for the Production of a Hemophilia Therapeutic
Mark Tié, Senior Associate Scientist, Biogen Idec

9:15
An Open Cell Free Protein Synthesis Platform to Discover Novel Antibodies and Bispecifics
Aaron K. Sato, Ph.D., Vice President, Research, Sutro Biopharma, Inc.

9:45
Networking Refreshment Break

Keynote Presentations

10:15
Matthew Croughan, Ph.D.
30 kg of Antibody Per Batch from High Density Single-Use Bioreactors
Matthew Croughan, Ph.D., Industry Professor, Amgen Bioprocessing Center and Founding Professor, Bioprocessing Program, Keck Graduate Institute

10:45
Michael Betenbaugh, Ph.D. Glyco Engineering:In Silico versus In Cells
Michael Betenbaugh, Ph.D., Professor and Chair, Johns Hopkins University

Cell Line Development and Modification for Novel Modalities and Difficult-to-Express Proteins

11:15
Cell Line Development for a Measles Vaccine as a Multiple Myeloma Treatment
Mark J. Federspiel, Ph.D., Director, Gene and Virus Therapy Shared Resource, Mayo Clinic Comprehensive Cancer Center

11:45
Technology Workshop Presentations

12:15
Lunch on your Own

1:25
Chairperson's Remarks
Arnaud Poterszman, Ph.D., Research Director, Integrated Structural Biology, IGBMC, Strasbourg University, France

Cell Line Development and Modification for Novel Modalities and Difficult-to-Express Proteins (Continued)

1:30
Presentation by MedImmune UK

2:00
Advances and Challenges in the Analytical Characterization of Biosimilar Products
Jeff Allen, Ph.D., Director of Protein Sciences, Pfenex

2:30
Advances in Baculovirus Expression for the Production of Difficult to Express Proteins and Complexes
Arnaud Poterszman, Ph.D., Research Director, Integrated Structural Biology, IGBMC, Strasbourg University, France

3:00
Roundtable Discussions & Networking Refreshment Break

Manufacturability Assessment Strategies

3:30
NGS Cell line Quality and/or Miss-Splicing and/or Manufacturability Screening Funnel
Stephanie Rieder, Ph.D., Principal Research Scientist, AbbVie

4:00
Early Detection of Sequence Variants During Cell Line Development
Scott Estes, Ph.D., Director, Cell Culture Development, Biogen Idec

4:30
Comparative Glycomics for Early Stage Quality Assessment of mAbs
Jonathan Bones, Ph.D., Principle Investigator, National Institute for Bioprocessing Research and Training, Ireland

5:00
Close of Conferences